Cancer nanomedicine: From targeted delivery to combination therapy

Xiaoyang Xu, William Ho, Xueqing Zhang, Nicolas Bertrand, Omid Farokhzad

Research output: Contribution to journalReview articlepeer-review

565 Scopus citations


The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of various diseases, including cancer. The unique properties of nanoparticles (NPs), such as large surface-to-volume ratio, small size, the ability to encapsulate various drugs, and tunable surface chemistry, give them many advantages over their bulk counterparts. This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload. These advantages make NPs a mode of treatment potentially superior to conventional cancer therapies. This review highlights the most recent developments in cancer treatment using NPs as drug delivery vehicles, including promising opportunities in targeted and combination therapy.

Original languageEnglish (US)
Pages (from-to)223-232
Number of pages10
JournalTrends in Molecular Medicine
Issue number4
StatePublished - Apr 1 2015

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology


  • Cancer
  • Combination therapy
  • Nanomedicine
  • Targeted delivery


Dive into the research topics of 'Cancer nanomedicine: From targeted delivery to combination therapy'. Together they form a unique fingerprint.

Cite this